PRGN-3007 / Precigen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PRGN-3007 / Precigen
MCC-21622, NCT05694364: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Recruiting
1
88
US
Fludarabine, Fludara, Cyclophosphamide, PRGN-3007
H. Lee Moffitt Cancer Center and Research Institute, Precigen, Inc
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
01/26
01/26

Download Options